glp-1 hypoglycemia Blockade of receptor prevents post-VSG but not injectible_hypoglycemic_drugs [TUSOM | Pharmwiki]

A composite analysis of 8 cardiovascular outcomes trials completed in 2021 demonstrated reduced incidence of major cardiovascular events by 14% and cardiovascular death by 13% (NCT01147250, NCT01179048, NCT01720446, NCT01144338, NCT02465515, NCT01394952, NCT02692716, NCT03496298)

The FDA has received reports of dosing errors associated with compounded GLP-1s, including patients accidentally taking too much or too little and experiencing complications such as fainting, dehydration and severe gastrointestinal symptoms

May form clumps

GLP-1 receptors are found in the heart and blood vessels, influencing blood pressure, lipid profiles, and inflammation

Based on your consent, we may share information about your website interactions (e.g., pages viewed, products interacted with) with advertising platforms such as Google and Meta for the purpose of creating advertising audiences and personalising ads across Vision Healthcare brands